Pathology Research International

Pathology Research International / 2011 / Article

Review Article | Open Access

Volume 2011 |Article ID 780652 | 7 pages |

Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management

Academic Editor: P. J. Van Diest
Received12 Jan 2011
Revised01 Jun 2011
Accepted07 Jun 2011
Published27 Jul 2011


Lung cancers account for a huge percentage of death in industrialized countries, and hence there is an increasing call for the development of novel treatments. These malignancies are caused by a combination of environmental factors, principally cigarette smoking and genetic alterations. MicroRNAs (miRNAs) are a recently discovered class of regulatory noncoding small RNAs with a significance in numerous biological processes. Strong evidence links miRNA impaired expression profiles and pathways to the etiology of several diseases, including neoplasia. This paper focuses on the emerging role of miRNA function in lung cancer development with particular highlighting on the use of miRNA profiles and polymorphisms for the molecular and biological characterization of tumor pulmonary growth and progression. Furthermore, we underline the potential utility of lung cancer-associated miRNAs as clinical biomarkers with a diagnostic, prognostic, and therapeutic significance and give emphasis to the promising novel miRNA-based curative strategies.

1. Introduction

Lung cancer is one of the commonest neoplasia and the first cause of death worldwide, in both women and men, with an increasing incidence rate. Less than 10% of people with the disease live longer than five years after diagnosis [1, 2]. Lung tumor is characterized by a preponderance of carcinoma derived from changes and abnormally growth of epithelial lung cells. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) are two main distinct types of this neoplasia that have considerable differences in pathogenetic mechanisms, cellular origin, molecular changes and histopathological and clinical features [1]. Furthermore, they show a different response to therapeutic treatments such as surgical resection, radiation, and chemotherapy. NSCLC comprises approximately 80% of all lung cancers and can be classified into adenocarcinoma (AC), squamous cell carcinoma (SqCC), and large cell carcinoma, whereas SCLC tends to spread more quickly than NSCLC and can be divided into small cell carcinoma (SCC), mixed small cell/large cell carcinoma, and combined small cell carcinoma. Symptoms can be absent or very moderate, mainly in the early stages of tumor transformation, so that a large percentage of patients is diagnosed only in advanced stage of tumor extension with a consequent poor treatment outcome. Although surgery provides a potential curative strategy, patients often develop recurrence with a survival rate that remains very low especially in subjects with metastatic disease. Therefore, looking for biomarkers able to accurately detect early tumor changes is the principle warrant in lung cancer management [3]. Different factors have been associated with an increased risk of lung cancer development, mainly cigarette smoke and air-carcinogens, as well as a family history of pulmonary tumor. Lung neoplasia has indeed a multifactorial etiology being caused by gene-gene and gene-environment interactions [4, 5]. The importance of genetic background in lung tumor has been well highlighted and, in recent years, microRNA- (miRNA or miR) specific signatures have been reported to play a critical role in cancer transformation. These molecules represent a novel potential class of sensitive markers for different and significant clinical applications.

2. MicroRNA Overview

MicroRNAs are evolutionarily conserved small noncoding RNAs that negatively regulate gene expression at the posttranscriptional level by repressing translation or decreasing mRNA stability [6, 7]. MiRNAs are initially transcribed by RNA polymerase II as long primary molecules (pri-miRNAs) that are processed in the nucleus into hairpin precursors (pre-miRNAs) via the RNase-III enzyme DROSHA and the RNA-binding protein DGCR8 [8]. Pre-miRNAs are further transported to the cytoplasm by RAN GTPase/Exportin 5 complex where they are matured into active miRNAs by RNase III enzyme Dicer [9]. Mature miRNA, a single-stranded RNA with a length of about 22 nucleotides, is incorporated into an RNA-induced silencing complex (RISC) by RNA processing proteins, such as AGO1 and AGO2 [10]; miRNA is now able to bind target transcripts through base pairing with their 3′-untranslated regions (UTRs). The sequence important for mRNA recognition encompasses bases 2 to 8 at the 5′-end of the mature miRNA, and it is known as the “seed sequence” [6].

To date, more than 800 miRNAs have been identified in the human genome [11], each of them having the potential capacity to bind to hundreds of transcripts, and the biological functions of most miRNAs are rapidly emerging. As estimated by in silico prediction algorithms [11, 12], miRNAs regulate at least 30% of the protein-encoding genes and are involved in a broad range of cellular processes such as proliferation, differentiation, homeostasis, and apoptosis, so it is not strange that the dysregulation into the miRNA pathway might contribute to human diseases, including cancer development. Distinct patterns of miRNA expression share common pathways and display a significant tumor specificity supporting their use as promising clinical and biological markers for different cancer aspects as formation, progression, diagnosis, prognosis, and response to therapy [1317].

2.1. MiR-Profiling in Lung Cancer

Since their discovery, increasing evidence indicates a deep involvement of miRNAs in human lung tumorigenesis by acting as tumor suppressors or oncogenes, largely by targeting proteins that are key regulators of cellular proliferation and survival, DNA repair, and immune response [18]. Expression of specific microRNAs is substantially changed in a number of different lung cancer types compared to nontumor lung tissues and cells [19, 20]. Furthermore, many of these miRNAs are located at chromosome regions which are frequently deleted or amplified in several malignancies [13, 21]. Let-7 was the first microRNA reported to have a role in lung cancer development [22]. Reduced levels of let-7 miRNA family members were found both in vitro and in vivo studies of human pulmonary neoplasia, and let-7-mediated tumor suppression was suggested to occur largely through the regulation of HMGA2 and RAS genes associated with cell division [20, 2224]; miR-126 expression in different lung tumor cell lines was inverse to the upregulated VEGF which resulted to be a direct target of miR-126 [25]. Chen et al. [26] showed that miR-145 amount was markedly decreased in NSCLC tumor specimens and in two human NSCLC cell lines, A549 and H23, relative to nonmalignant lung tissues and cells, respectively. MiR-145 has been shown to act as an antioncogenic molecule able to inhibit proliferation and the G1/S transition of lung cancer cells by affecting c-Myc/eIF4E4/CDK4 protein levels without changes in apoptosis [27]. Dysregulation of miR-451 correlated with the development of non-small cell lung cancer by enhancing apoptosis probably through the inactivation of Akt signaling pathway [28]. In particular, downregulation of miR-451 was significantly associated with strong positive immunoreactivity of RAB14 protein, a member of RAS oncogene family. Although the majority of miRNAs have been proposed to operate as tumor suppressors in lung cancer, as suggested by their overall downregulation, an increasing number of miRNAs have been found to have oncogenic properties. Overexpression of miR-17-92, miR-31, miR-21, and miR-7 significantly enhanced proliferation and tumorigenicity of lung cancer cells largely by inhibiting negative regulators of oncogenic pathways [20, 2932].

Moreover, miRNA expression signatures strictly correlate with tumor development and progression, also at an early stage, and give significant improvement in the molecular characterization and biological classification of a wide variety of human cancers, including lung malignancy [15, 33, 34]. For example, Yanaihara et al. [19] showed that a subset of miRNAs was differently expressed in adenocarcinomas and squamous cell carcinomas, with miR-99b and miR-102 showing higher levels in ACs. Overexpression of miR-205 was only detected in SqCCs but not in ACs, and an accurate distinction of the two NSCLC types was allowed by monitoring its levels just in the early phases of cancer transformation [35]. It has been speculated that the use of microRNAs as tumor stage markers might also avoid the variability in the pulmonary cancer subclassification observed with the conventional histopathologic and immunohistochemical techniques due to quality/quantity limitations of bioptic material and staining interpretation [15, 33, 36, 37]. The definition of lung carcinoma subclasses with respect to miRNA quantification is extremely sensitive and specific owing the high stability of miRNAs even in poorly conserved specimens and to the advanced technologies used for their detection as Real-Time PCR and Microarray [15].

MiRNA profiling was also linked to clinicopathological tumor features and lung cancer patient outcome, thus having a potential diagnostic and prognostic impact [3840]. Downregulation of miR-125a-3p and miR-125a-5p in non-small cell lung carcinomas predicted a more aggressive clinical course by promoting tumor invasion and lymph node metastasis [41]. Low levels of let-7a-2 in combination with specific expression changes in other microRNAs associated with poor survival in patients with lung adenocarcinoma [19, 38]. The expression level of miR-451 was found to be significantly associated with NSCLC tumor differentiation, pathological stage, lymph node metastasis, and shorter overall survival of patients [28]. Elevated levels of miR-21, miR-17, and miR-155 were associated with cancer-specific mortality and disease-free survival in NSCLC patients from Maryland, Norway, and Japan [42]. In particular, increased miR-21 expression was found in advanced stage tumors in all the three different cohorts supporting its prognostic value for lung adenocarcinoma. A recent work by Arora et al. [43] gave evidence of the importance to test the expression of miR-328 in NSCLC samples since it correctly classified patients at higher risk for developing brain metastasis. Moreover, several lines of evidence suggest that microRNA deregulation in lung tumors may also predict disease recurrence and/or response to adjuvant anticancer treatments, such as curative surgery, chemotherapy, and radiotherapy [44, 45]. Downregulation of microRNA-128b, due to loss of heterozygosity of 3p22 in lung tumor specimens, was associated to increased epidermal growth factor receptor (EGFR) expression with a consequent survival benefit in patients treated with gefitinib, a EGFR-tyrosine kinase inhibitor drug commonly used in advanced NSCLC management [13]. High levels of miR-92a-2* correlated with chemoresistance and decreased survival of SCLC cases [46], whereas let-7 family of miRNAs could augment sensibility to radiation in lung cancer cells [47]. Furthermore, reduced expression of let-7 in NSCLC tissues was indicative of elevated postoperative risk of death of the surgically treated patients [22]. Taken together, all these observations suggest that the evaluation of expression changes just in a subset of miRNAs might give important information of practical use in clinical trials for the management of lung oncologic patients since efficacy of therapeutic treatments mainly depends on accurate and early tumor definition [3]. Moreover, microRNA profiling results to have a predictive, diagnostic, and prognostic application that can avoid the use of aggressive tools, such as computed tomography, in lung tumor detection and management [48]. The presence of stably expressed and quantifiable miRNA levels in human serum, which are able to discriminate between normal and lung cancer samples, is an exciting discovery that strengthens the use of these small regulatory molecules as novel noninvasive biomarkers in lung cancer [4951]. In particular, serum miRNA detection might have the advantage to early select patients for appropriate treatment strategies in order to enhance their survival chance. However, results obtained among different studies suggest that circulating miRNA quantification needs accurate standardization before the potential as a screening tool in the management of lung cancer may be realized. In this regard, an important goal was obtained by Yu et al. [52] that developed a highly sensitive and specific panel of miRNAs for the early detection of lung adenocarcinoma in sputum. In particular, miR-21, miR-486, miR-375, and miR-200b showed a significantly different expression in lung adenocarcinoma patients versus normal subjects and their combined values were able to distinguish affected individuals from healthy controls with 80.6% sensitivity and 91.7% specificity in independent populations.

2.2. MiR-Polymorphisms and Lung Tumor Susceptibility

New findings have shown that alterations of miRNA expression or activity in cancers can be due to sequence variations in miRNA gene regions, in genes involved in miRNA biosynthesis or at binding sites in the 3′-UTR of miRNA target genes, collectively referred to as “miR-polymorphisms” [17, 5355]. Single-nucleotide polymorphisms (SNPs) might indeed affect miRNA primary transcript formation and expression, miRNA processing and maturation, and/or miRNA-target interactions. The role of polymorphisms in miRNA sequences and in genes involved into miRNA biogenesis is rapidly emerging and several studies have demonstrated their role in a wide spectrum of malignancies, including lung cancer [5459]. In particular, miRNA genetic variants might have a potential clinical utility being predictors of lung tumor predisposition. The rs11614913T>C SNP in the miRNA-196a2 sequence increased mature miRNA expression and target binding activity. Moreover, case-control studies in different ethnic populations showed that the CC genotype was significantly associated to an increased risk of lung cancer, particularly SqCC type, and predicted a reduced patient survival [56, 60]. Kim et al. [61] found that AGO1 rs636832A>G could modulate susceptibility to lung neoplasia since both the heterozygotes and homozygotes for the G allele had a decreased risk of lung cancer compared with subjects carrying the AA genotype. The genetic variation rs712T>G in a let-7 miRNA binding site in the 3′-UTR of K-RAS transcript was found to significantly increase the risk of NSCLC, especially by stratifying individuals for smoking history, through the oncogene upregulation [62]. Additional replication studies in other populations and in vitro experiments for the characterization of the biological significance of these particular SNPs are required to validate these findings. Nevertheless, screening for miR-polymorphisms could lead to better define the genetic risk to lung carcinogenesis as well as its recurrence development. For instance, miR-SNP genotypes and/or haplotypes might allow to categorize lung tumor patients into low, medium, and high-risk groups of disease with respect to determinate clinical aspects, such as cancer progression, chance of survival, and response to therapies. Combinations of various unfavorable SNPs could more accurately identify the risk of cancer for each individual. In a recent work, Rotunno et al. [63] showed that the GTAATC haplotype in RNASEN, coding for Drosha, connected with lung cancer-specific reduced survival; moreover, a variant allele of rs640831 was significantly associated with RNASEN reduced mRNA expression and with changes in the levels of particular microRNAs only in adenocarcinomas but not in SqCC samples.

Hence, the potential prognostic implications of microRNA-related genetic variations in lung cancer may be used for developing novel personalized therapeutic applications and for checking patient outcome.

2.3. MiR-Based Therapies in Lung Cancer

The accumulated data on miRNA role as oncogenes or tumor suppressors in lung carcinogenesis suggest that miR-based applications in cancer medicine are an attractive and promising area for patient cure. Indeed, if aberrant microRNA levels are found into tumor tissues, restoring specific microRNA expression might have therapeutic implications. Recent research activities have been focused on the discovery of new molecules able to selectively and stably interfere with microRNA regulatory networks and on the evaluation of the efficacy, stability, tolerability, and cost of the miR-based therapeutic agents. In this context, therapies for knocking down specific miRNAs with oncogenic activity are potentially based on antisense miRNA modified-oligonucleotides, also known as antagomirs, miRNA sponges, miRNA masking, and small molecule inhibitors, while miRNA mimics might be useful in the reintroduction of miRNAs with tumor suppressor capability [14, 64, 65]. Experimental and preclinical data demonstrated that the restoration of cancer-related microRNA expression changes to normal levels by miRNA mimics or antagomirs could reverse the cancer phenotype in tumor cells and in animal models of human neoplasia [66, 67]. In particular, mice intranasally inoculated with adenovirus expressing let-7a microRNA showed decreased pulmonary tumor formation in comparison to animals treated with a scrambled sequence [68]. Indication that replacement of let-7 family members may effectively interfere with lung carcinogenesis in vivo was also confirmed by a recent study by Trang et al. [69] in which let-7 intranasal injection of mice led to reduced tumor lung size. Liposomal delivery of chemically synthesized miR-34a in mouse models of NSCLC was specifically able to restore microRNA expression, to silence down-stream targets, and to inhibit lung tumor growth without inducing an immune response, a pivotal characteristic for a clinical application in tumor patient treatment [70]. Despite these positive results, several limitations need to be overcome before miRNA-based approaches might be successfully used in human lung cancer treatment either alone or in combination with conventional therapies. Continuous studies are strongly required in order to increase miRNAs specific and efficient tissue delivery, to improve microRNA stability, to keep constant their activity, and to prevent off-target effects, immune stimulation, and toxicity. To this regard, nonviral nanoparticle-based gene/RNA-delivery vectors seem to be a promising system for an efficient miRNA cellular uptake [71]. An efficient transport and delivery was obtained by encapsulating microRNAs into high-density lipoproteins or cationic liposomes [72, 73]. Ligands or monoclonal antibodies that recognize tumor-specific receptors could be conjugated to mimics/antagomirs in order to target miRNAs at the disease site selectively [74, 75]. Strategies for preventing nuclease degradation and increasing miRNA half life are essentially linked to chemical modifications of the RNA backbone such as 2′-fluoro/2′-methoxyethyl groups, phosphorothioate bonds, and nucleobases [76, 77]. In addition, an extremely precise definition of the specific miRNA levels and molecular mechanisms in the different lung cancer types and subtypes is necessary to identify novel targets which might be used for the development of new therapeutic strategies. In this context, interesting studies have demonstrated that DNMT3A and DNMT3B, two DNA methyltransferases involved in epigenetic cellular control, were direct targets of miR-29s and their over-expression inversely correlated with miR-29s levels in NSCLC, suggesting that drugs able to normalize DNA methylation patterns might be used in clinical trials as lung anticancer agents [78, 79].

3. Conclusions

Lung cancer is one of the main causes of cancer-related deaths in industrialized countries with only 15% of all patients surviving five years or more. Surgical resection of tumor tissues is the only actual chance of life, together with chemotherapy and/or radiotherapy for some individuals. MicroRNAs are a class of endogenous small regulatory RNAs that negatively control gene expression at the posttranscriptional level. Impaired expression of specific miRNAs has been associated with lung cancer pathogenesis in several studies and microRNA profiles might serve as novel biomarkers to predict cancer progression, prognosis, genetic risk, recurrence, and drug sensitivity (Table 1). Ameliorating the acknowledgements of specific miRNA regulators, tumor functions, downstream targets, and signaling pathways in lung cancer is essential for elucidating complex regulatory networks that are critical for the malignancy biology. These findings will have to be focused on the development of novel preventive and curative treatments. MiRNA mimics or antisense oligonucleotides are indeed promising new tools for cancer therapy.

MicroRNAExpressionTarget/FunctionClinical value

let-7 familyDownHMGA2, RAS, Myc, cell divisionAssociated with cancer-specific mortality and disease-free survival; increased sensibility to radiation; elevated postoperative risk of death; rs712GG genotype in K-RAS 3′-UTR associated with increased risk of NSCLC
let-7a-2DownPoor survival in AC patients
miR-17Upcell proliferationAssociated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC
miR-102UpHigher levels in AC than in SqCC
miR-125a-3p/5pDownAssociated with tumor invasion and lymph node metastasis
miR-128bDownEGFRBenefit in patients treated with gefitinib
miR-145Downc-Myc, eIF4E4, CDK4
miR-155UpAssociated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC
miR-196a2Uprs11614913CC genotype associated with increased risk of lung cancer and reduced overall survival
miR-20bDownAssociated with advanced stages and lymph node metastasis
miR-21DownK-RAS, cell proliferationAssociated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC; able to discriminate lung cancer from healthy controls
miR-29sDownDNMT3A, DNMT3B
miR-205UpOnly detected in SqCC
miR-31UpLATS2, PPP2R2A, cell proliferation
miR-328Upcell migrationAssociated with higher risk of brain metastasis development
Associated with overall survival
miR-451DownRAB14, apoptosisAssociated with NSCLC stage, lymph node metastasis, and poor survival
miR-7UpEts2, cell proliferation
miR-92a-2*UpChemoresistance and decreased survival of SCLC cases
miR-99bUpHigher levels in AC than in SqCC

NSCLC: non-small cell lung carcinoma; AC: adenocaercinoma; SqCC: squamous cell carcinoma.


  1. P. C. Hoffman, A. M. Mauer, and E. E. Vokes, “Lung cancer,” Lancet, vol. 355, no. 9202, pp. 479–485, 2000. View at: Google Scholar
  2. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at: Publisher Site | Google Scholar
  3. R. Sangha, J. Price, and C. A. Butts, “Adjuvant therapy in non-small cell lung cancer: current and future directions,” Oncologist, vol. 15, no. 8, pp. 862–872, 2010. View at: Publisher Site | Google Scholar
  4. P. P. Massion and D. P. Carbone, “The molecular basis of lung cancer: molecular abnormalities and therapeutic implications,” Respiratory Research, vol. 41, no. 1, pp. 12–26, 2003. View at: Publisher Site | Google Scholar
  5. J. Clavel, “Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer,” Comptes Rendus Biologies, vol. 330, no. 4, pp. 306–317, 2007. View at: Publisher Site | Google Scholar
  6. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at: Publisher Site | Google Scholar
  7. M. A. Valencia-Sanchez, J. Liu, G. J. Hannon, and R. Parker, “Control of translation and mRNA degradation by miRNAs and siRNAs,” Genes and Development, vol. 20, no. 5, pp. 515–524, 2006. View at: Publisher Site | Google Scholar
  8. A. M. Denli, B. B. Tops, R. H. Plasterk, R. F. Ketting, and G. J. Hannon, “Processing of primary microRNAs by the Microprocessor complex,” Nature, vol. 432, no. 7014, pp. 231–235, 2004. View at: Publisher Site | Google Scholar
  9. V. N. Kim, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376–385, 2005. View at: Publisher Site | Google Scholar
  10. S. Griffiths-Jones, H. K. Saini, S. van Dongen, and A. J. Enright, “miRBase: tools for microRNA genomics,” Nucleic Acids Research, vol. 36, supplement 1, pp. D154–D158, 2008. View at: Publisher Site | Google Scholar
  11. M. Yoda, T. Kawamata, Z. Paroo et al., “ATP-dependent human RISC assembly pathways,” Nature Structural & Molecular Biology, vol. 17, no. 1, pp. 17–23, 2010. View at: Publisher Site | Google Scholar
  12. E. Berezikov, V. Guryev, J. van de Belt, E. Wienholds, R. H. A. Plasterk, and E. Cuppen, “Phylogenetic shadowing and computational identification of human microRNA genes,” Cell, vol. 120, no. 1, pp. 21–24, 2005. View at: Publisher Site | Google Scholar
  13. G. J. Weiss, L. T. Bemis, E. Nakajima et al., “EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines,” Annals of Oncology, vol. 19, no. 6, pp. 1053–1059, 2008. View at: Publisher Site | Google Scholar
  14. A. G. Bader, D. Brown, and M. Winkler, “The promise of microRNA replacement therapy,” Cancer Research, vol. 70, no. 18, pp. 7027–7030, 2010. View at: Publisher Site | Google Scholar
  15. J. A. Bishop, H. Benjamin, H. Cholakh, A. Chajut, D. P. Clark, and W. H. Westra, “Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach,” Clinical Cancer Research, vol. 16, no. 2, pp. 610–619, 2010. View at: Publisher Site | Google Scholar
  16. R. Hummel, D. J. Hussey, and J. Haier, “MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types,” European Journal of Cancer, vol. 46, no. 2, pp. 298–311, 2010. View at: Publisher Site | Google Scholar
  17. P. J. Mishra and J. R. Bertino, “MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine,” Pharmacogenomics, vol. 10, no. 3, pp. 399–416, 2009. View at: Publisher Site | Google Scholar
  18. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “MicroRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007. View at: Publisher Site | Google Scholar
  19. N. Yanaihara, N. Caplen, E. Bowman et al., “Unique microRNA molecular profiles in lung cancer diagnosis and prognosis,” Cancer Cell, vol. 9, no. 3, pp. 189–198, 2006. View at: Publisher Site | Google Scholar
  20. H. Osada and T. Takahashi, “let-7 and miR-17-92: small-sized major players in lung cancer development,” Cancer Science, vol. 102, no. 1, pp. 9–17, 2011. View at: Publisher Site | Google Scholar
  21. G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999–3004, 2004. View at: Publisher Site | Google Scholar
  22. J. Takamizawa, H. Konishi, K. Yanagisawa et al., “Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival,” Cancer Research, vol. 64, no. 11, pp. 3753–3756, 2004. View at: Publisher Site | Google Scholar
  23. Y. S. Lee and A. Dutta, “The tumor suppressor microRNA let-7 represses the HMGA2 oncogene,” Genes and Development, vol. 21, no. 9, pp. 1025–1030, 2007. View at: Publisher Site | Google Scholar
  24. M. S. Kumar, S. J. Erkeland, R. E. Pester et al., “Suppression of non-small cell lung tumor development by the let-7 microRNA family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3903–3908, 2008. View at: Publisher Site | Google Scholar
  25. B. Liu, X. C. Peng, X. L. Zheng, J. Wang, and Y. W. Qin, “MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo,” Lung Cancer, vol. 66, no. 2, pp. 169–175, 2009. View at: Publisher Site | Google Scholar
  26. Z. Chen, H. Zeng, Y. Guo et al., “miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc,” Journal of Experimental & Clinical Cancer Research, vol. 29, no. 1, pp. 151–160, 2010. View at: Publisher Site | Google Scholar
  27. W. Cho, A. Chow, and J. Au, “MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1,” RNA Biology, vol. 8, no. 1, pp. 125–131, 2011. View at: Publisher Site | Google Scholar
  28. R. Wang, Z. X. Wang, J. S. Yang, X. Pan, W. De, and L. B. Chen, “MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14),” Oncogene, vol. 30, no. 23, pp. 2644–2658, 2011. View at: Publisher Site | Google Scholar
  29. Y. Hayashita, H. Osada, Y. Tatematsu et al., “A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation,” Cancer Research, vol. 65, no. 21, pp. 9628–9632, 2005. View at: Publisher Site | Google Scholar
  30. Y. T. Chou, H. H. Lin, Y. C. Lien et al., “EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF,” Cancer Research, vol. 70, no. 21, pp. 8822–8831, 2010. View at: Publisher Site | Google Scholar
  31. M. E. Hatley, D. M. Patrick, M. R. Garcia et al., “Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21,” Cancer Cell, vol. 18, no. 3, pp. 282–293, 2010. View at: Publisher Site | Google Scholar
  32. X. Liu, L. F. Sempere, H. Ouyang et al., “MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1298–1309, 2010. View at: Publisher Site | Google Scholar
  33. J. Lu, G. Getz, E. A. Miska et al., “MicroRNA expression profiles classify human cancers,” Nature, vol. 435, no. 7043, pp. 834–838, 2005. View at: Publisher Site | Google Scholar
  34. M. T. Landi, Y. Zhao, M. Rotunno et al., “MicroRNA expression differentiates histology and predicts survival of lung cancer,” Clinical Cancer Research, vol. 16, no. 2, pp. 430–441, 2010. View at: Publisher Site | Google Scholar
  35. D. Lebanony, H. Benjamin, S. Gilad et al., “Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2030–2037, 2009. View at: Publisher Site | Google Scholar
  36. A. R. Feinstein, N. A. Gelfman, R. Yesner et al., “Observer variability in the histopathologic diagnosis of lung cancer,” American Review of Respiratory Disease, vol. 101, no. 5, pp. 671–684, 1970. View at: Google Scholar
  37. J. B. Sorensen, F. R. Hirsch, A. Gazdar, and J. E. Olsen, “Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma,” Cancer, vol. 71, no. 10, pp. 2971–2976, 1993. View at: Google Scholar
  38. S. L. Yu, H. Y. Chen, G. C. Chang et al., “MicroRNA signature predicts survival and relapse in lung cancer,” Cancer Cell, vol. 13, no. 1, pp. 48–57, 2008. View at: Publisher Site | Google Scholar
  39. W. Gao, Y. Yu, H. Cao et al., “Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis,” Biomedicine & Pharmacotherapy, vol. 64, no. 6, pp. 399–408, 2010. View at: Publisher Site | Google Scholar
  40. A. Navarro, T. Diaz, E. Gallardo et al., “Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer,” Journal of Surgical Oncology, vol. 103, no. 5, pp. 411–415, 2011. View at: Publisher Site | Google Scholar
  41. L. Jiang, Q. Huang, S. Zhang et al., “Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells,” BMC Cancer, vol. 10, pp. 318–330, 2010. View at: Publisher Site | Google Scholar
  42. M. Saito, A. J. Schetter, S. Mollerup et al., “The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts,” Clinical Cancer Research, vol. 17, no. 7, pp. 1875–1882, 2011. View at: Publisher Site | Google Scholar
  43. S. Arora, A. R. Ranade, N. L. Tran et al., “MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration,” International Journal of Cancer. In press. View at: Publisher Site | Google Scholar
  44. R. Hummel, D. J. Hussey, and J. Haier, “MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types,” European Journal of Cancer, vol. 46, no. 2, pp. 298–311, 2010. View at: Publisher Site | Google Scholar
  45. S. K. Patnaik, E. Kannisto, S. Knudsen, and S. Yendamuri, “Evaluation of microRNA expression profiles that may predict after surgical resection recurrence of localized stage i non-small cell lung cancer,” Cancer Research, vol. 70, no. 1, pp. 36–44, 2010. View at: Publisher Site | Google Scholar
  46. A. R. Ranade, D. Cherba, S. Sridhar et al., “MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 8, pp. 1273–1278, 2010. View at: Publisher Site | Google Scholar
  47. J. B. Weidhaas, I. Babar, S. M. Nallur et al., “MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy,” Cancer Research, vol. 67, no. 23, pp. 11111–11116, 2007. View at: Publisher Site | Google Scholar
  48. M. Boeri, C. Verri, D. Conte et al., “MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3713–3718, 2011. View at: Publisher Site | Google Scholar
  49. Z. Hu, X. Chen, Y. Zhao et al., “Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1721–1726, 2010. View at: Publisher Site | Google Scholar
  50. J. Shen, N. W. Todd, H. Zhang et al., “Plasma microRNAs as potential biomarkers for non-small-cell lung cancer,” Laboratory Investigation, vol. 91, no. 4, pp. 579–587, 2011. View at: Publisher Site | Google Scholar
  51. W. Gao, L. Liu, X. Lu, and Y. Shu, “Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma,” Clinical Lung Cancer, vol. 12, no. 1, pp. 14–17, 2011. View at: Publisher Site | Google Scholar
  52. L. Yu, N. W. Todd, L. Xing et al., “Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers,” International Journal of Cancer, vol. 127, no. 12, pp. 2870–2878, 2010. View at: Publisher Site | Google Scholar
  53. R. Duan, C. Pak, and P. Jin, “Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA,” Human Molecular Genetics, vol. 16, no. 9, pp. 1124–1131, 2007. View at: Publisher Site | Google Scholar
  54. Z. Yu, Z. Li, N. Jolicoeur et al., “Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers,” Nucleic Acids Research, vol. 35, no. 13, pp. 4535–4541, 2007. View at: Publisher Site | Google Scholar
  55. X. Pu, C. Lu, D. J. Stewart et al., “MicroRNA-related genetic variants as predictors of early stage non–small cell lung cancer clinical outcomes,” Cancer Epidemiology Biomarkers & Prevention, vol. 20, no. 4, p. 719, 2011. View at: Google Scholar
  56. Z. Hu, J. Chen, T. Tian et al., “Genetic variants of miRNA sequences and non-small cell lung cancer survival,” Journal of Clinical Investigation, vol. 118, no. 7, pp. 2600–2608, 2008. View at: Publisher Site | Google Scholar
  57. M. Wu, N. Jolicoeur, Z. Li et al., “Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs,” Carcinogenesis, vol. 29, no. 9, pp. 1710–1716, 2008. View at: Publisher Site | Google Scholar
  58. M. S. Nicoloso, H. Sun, R. Spizzo et al., “Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility,” Molecular and Cellular Pathobiology, vol. 70, no. 7, pp. 2789–2798, 2010. View at: Publisher Site | Google Scholar
  59. B. M. Ryan, A. I. Robles, and C. C. Harris, “Genetic variation in microRNA networks: the implications for cancer research,” Nature Reviews Cancer, vol. 10, no. 6, pp. 389–402, 2010. View at: Publisher Site | Google Scholar
  60. T. Tian, Y. Shu, J. Chen et al., “A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese,” Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 4, pp. 1183–1187, 2009. View at: Publisher Site | Google Scholar
  61. J. S. Kim, Y. Y. Choi, G. Jin et al., “Association of a common AGO1 variant with lung cancer risk: a two-stage case-control study,” Molecular Carcinogenesis, vol. 49, no. 10, pp. 913–921, 2010. View at: Publisher Site | Google Scholar
  62. L. J. Chin, E. Ratner, S. Leng et al., “A SNP in a let-7 microRNA complementary site in the KRAS 3'UTR increases non-small cell lung cancer risk,” Cancer Research, vol. 68, no. 20, pp. 8535–8540, 2008. View at: Publisher Site | Google Scholar
  63. M. Rotunno, Y. Zhao, A. W. Bergen et al., “Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival,” British Journal of Cancer, vol. 103, no. 12, pp. 1870–1874, 2010. View at: Publisher Site | Google Scholar
  64. Z. Liu, A. Sall, and D. Yang, “MicroRNA: an emerging therapeutic target and intervention tool,” International Journal of Molecular Sciences, vol. 9, no. 6, pp. 978–999, 2008. View at: Publisher Site | Google Scholar
  65. C. Li, Y. Feng, G. Coukos, and L. Zhang, “Therapeutic microRNA strategies in human cancer,” The AAPS Journal, vol. 11, no. 4, pp. 747–757, 2009. View at: Publisher Site | Google Scholar
  66. J. Kota, R. R. Chivukula, K. A. O'Donnell et al., “Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model,” Cell, vol. 137, no. 6, pp. 1005–1017, 2009. View at: Publisher Site | Google Scholar
  67. O. A. Kent, R. R. Chivukula, M. Mullendore et al., “Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway,” Genes and Development, vol. 24, no. 24, pp. 2754–2759, 2010. View at: Publisher Site | Google Scholar
  68. A. Esquela-Kerscher, P. Trang, J. F. Wiggins et al., “The let-7 microRNA reduces tumor growth in mouse models of lung cancer,” Cell Cycle, vol. 7, no. 6, pp. 759–764, 2008. View at: Google Scholar
  69. P. Trang, P. P. Medina, J. F. Wiggins et al., “Regression of murine lung tumors by the let-7 microRNA,” Oncogene, vol. 29, no. 11, pp. 1580–1587, 2010. View at: Publisher Site | Google Scholar
  70. J. F. Wiggins, L. Ruffino, K. Kelnar et al., “Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34,” Cancer Research, vol. 70, no. 14, pp. 5923–5930, 2010. View at: Publisher Site | Google Scholar
  71. X. Pan, R. Thompson, X. Meng et al., “Tumor-targeted RNA-interference: functional non-viral nanovectors,” American Journal of Cancer Research, vol. 1, no. 1, pp. 25–42, 2011. View at: Google Scholar
  72. P. Li, D. Liu, X. Sun, C. Liu, Y. Liu, and N. Zhang, “A novel cationic liposome formulation for efficient gene delivery via a pulmonary route,” Nanotechnology, vol. 22, no. 24, Article ID 245104, 2011. View at: Publisher Site | Google Scholar
  73. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, “MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins,” Nature Cell Biology, vol. 13, no. 4, pp. 423–433, 2011. View at: Publisher Site | Google Scholar
  74. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang, “Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy,” Molecular Therapy, vol. 18, no. 9, pp. 1650–1656, 2010. View at: Publisher Site | Google Scholar
  75. Y. Chen, S. R. Bathula, Q. Yang, and L. Huang, “Targeted nanoparticles deliver siRNA to melanoma,” Journal of Investigative Dermatology, vol. 12, no. 12, pp. 2790–2798, 2010. View at: Publisher Site | Google Scholar
  76. S. Davis, S. Propp, S. M. Freier et al., “Potent inhibition of microRNA in vivo without degradation,” Nucleic Acids Research, vol. 37, no. 1, pp. 70–77, 2009. View at: Publisher Site | Google Scholar
  77. H. Peacock, R. V. Fucini, P. Jayalath et al., “Nucleobase and ribose modifications control immunostimulation by a MicroRNA-122-mimetic RNA,” Journal of American Chemical Society, vol. 133, no. 24, pp. 9200–9203, 2011. View at: Google Scholar
  78. J. C. Chuang and P. A. Jones, “Epigenetics and microRNAs,” Pediatric Research, vol. 61, no. 5, pp. 24R–29R, 2007. View at: Publisher Site | Google Scholar
  79. M. Fabbri, R. Garzon, A. Cimmino et al., “MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 40, pp. 15805–15810, 2007. View at: Publisher Site | Google Scholar

Copyright © 2011 Francesca Megiorni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1695 Views | 852 Downloads | 11 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder